| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Keiran S M Smalley | Q61525717 |
| P2093 | author name string | Daniel Abate-Daga | |
| Peter A Forsyth | |||
| Inna Smalley | |||
| Maria C Ramello | |||
| P2860 | cites work | Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas | Q24303940 |
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Efficient tumour formation by single human melanoma cells | Q24648938 | ||
| CAR models: next-generation CAR modifications for enhanced T-cell function | Q26745600 | ||
| Astrocytes: biology and pathology | Q27490746 | ||
| Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling | Q27851628 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors | Q28468571 | ||
| Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis | Q28594356 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Pericytes regulate the blood-brain barrier | Q29615840 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Cerebral glucose metabolism and the glutamine cycle as detected by in vivo and in vitro 13C NMR spectroscopy | Q30931852 | ||
| Real-time imaging reveals the single steps of brain metastasis formation | Q33519908 | ||
| Energy on demand | Q48283930 | ||
| Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? | Q48351638 | ||
| In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain | Q48401147 | ||
| PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo | Q48447011 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| Activation of stat3 in human melanoma promotes brain metastasis | Q48616814 | ||
| Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes | Q48822903 | ||
| Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers | Q49627232 | ||
| Making a tumour's bed: glioblastoma stem cells and the vascular niche. | Q51977217 | ||
| Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. | Q52646854 | ||
| Astrocytes induce blood–brain barrier properties in endothelial cells | Q57318253 | ||
| Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma | Q82849769 | ||
| Prognostic factors for survival in melanoma patients with brain metastases | Q85226494 | ||
| FDA Approves Second CAR T-cell Therapy | Q89852114 | ||
| Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib | Q45896654 | ||
| Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy | Q46096916 | ||
| Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. | Q47653459 | ||
| Emerging targets in cancer immunotherapy | Q47682070 | ||
| Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy | Q47693087 | ||
| Lessons from CTLA-4 deficiency and checkpoint inhibition | Q47955601 | ||
| Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma | Q48198483 | ||
| Neurons and astrocytes secrete factors that cause stem cells to differentiate into neurons and astrocytes, respectively | Q48264873 | ||
| Adaptation of energy metabolism in breast cancer brain metastases | Q48269541 | ||
| Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | Q33561644 | ||
| Central nervous system pericytes in health and disease | Q33609398 | ||
| Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. | Q33882549 | ||
| Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis | Q33901776 | ||
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial | Q33926135 | ||
| Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. | Q33930593 | ||
| Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells | Q33946698 | ||
| Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial | Q34066501 | ||
| Reactive Astrocytes Protect Melanoma Cells from Chemotherapy by Sequestering Intracellular Calcium through Gap Junction Communication Channels | Q34105366 | ||
| Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer | Q34393640 | ||
| Serpins promote cancer cell survival and vascular co-option in brain metastasis | Q34407528 | ||
| Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target | Q34438536 | ||
| Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations | Q34438555 | ||
| Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S | Q34599128 | ||
| Complete regression of a previously untreated melanoma brain metastasis with ipilimumab | Q34617578 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy | Q34633703 | ||
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 | ||
| Surgical management of melanoma brain metastases in patients treated with immunotherapy. | Q34954990 | ||
| Melanoma brain colonization involves the emergence of a brain-adaptive phenotype | Q34971850 | ||
| Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain | Q35044463 | ||
| Astrocytes directly influence tumor cell invasion and metastasis in vivo | Q35063834 | ||
| Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma | Q35101351 | ||
| Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis | Q35409064 | ||
| PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis | Q35417215 | ||
| The management of brain metastases | Q35571251 | ||
| The biology of brain metastases-translation to new therapies | Q35676602 | ||
| Brain metastases in melanoma: roles of neurotrophins | Q35768716 | ||
| Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites | Q35812429 | ||
| CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. | Q36023980 | ||
| Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma | Q36027584 | ||
| Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer | Q36051379 | ||
| Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) | Q36057973 | ||
| AKT1 Activation Promotes Development of Melanoma Metastases. | Q36284645 | ||
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | Q36338753 | ||
| Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases | Q36533041 | ||
| Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases | Q36597510 | ||
| Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases | Q36642420 | ||
| Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain | Q36685941 | ||
| Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth | Q36761252 | ||
| Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells | Q36888327 | ||
| The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. | Q37020840 | ||
| Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets | Q37028708 | ||
| Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization | Q37185154 | ||
| Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases | Q37231972 | ||
| Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer | Q37252611 | ||
| Ipilimumab and radiation therapy for melanoma brain metastases | Q37481186 | ||
| Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients | Q37544396 | ||
| Exploiting the curative potential of adoptive T-cell therapy for cancer | Q37576033 | ||
| Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma | Q37727061 | ||
| Oligodendroglia: metabolic supporters of axons | Q38132499 | ||
| Novel treatments for melanoma brain metastases | Q38146716 | ||
| Determinants of outcome in melanoma patients with cerebral metastases | Q38517839 | ||
| Evolving treatment options for melanoma brain metastases | Q38598521 | ||
| The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. | Q38614374 | ||
| Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. | Q38737680 | ||
| Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases | Q38752122 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future | Q38763111 | ||
| The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation | Q38766447 | ||
| Melanoma central nervous system metastases: current approaches, challenges, and opportunities | Q38807942 | ||
| Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model | Q38811717 | ||
| Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. | Q39610715 | ||
| Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer | Q39721426 | ||
| Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model | Q40374398 | ||
| Molecular characterization of breast cancer CTCs associated with brain metastasis | Q41242728 | ||
| Extravascular migration of tumor cells in the brain: an electron microscopic study. | Q42469994 | ||
| Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment | Q42547688 | ||
| Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 | ||
| Successful treatment of melanoma brain metastases with adoptive cell therapy. | Q42933679 | ||
| Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. | Q43022293 | ||
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 | ||
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-12-23 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | The biology and therapeutic management of melanoma brain metastases |
| Q89861115 | Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers |
| Q93017129 | Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors |
| Q57167169 | Low-Intensity MR-Guided Focused Ultrasound Mediated Disruption of the Blood-Brain Barrier for Intracranial Metastatic Diseases |
Search more.